CGEN cgen.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Compugen Ltd. (CGEN) enjoys global recognition as an innovator in AI-driven target discovery for tumor therapies, while its digital research format minimizes environmental impact and reduces waste. This price chart illustrates the EV/EBITDA multiple, which currently stands at 0.00. However, financial stability relies on licensee payments, and R&D expenditures create a risk of losses should clinical trials fail.

This indicator correlates the total business value, including net debt, with its operating profit before taxes, depreciation, and amortization. The metric determines the asset's real price by neutralizing the impact of debt load and tax regimes. An analysis of the Enterprise Value to EBITDA ratio reveals the issuer's overvaluation during periods of low liquidity. For Compugen Ltd. (CGEN), this is critical, as dependence on a single IT platform and binary development risks necessitate strict control over fundamental value.